Letters
23 July 2025
Early Access
Acute generalized exanthematous pustulosis triggered by dupilumab
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
131
Views
51
Downloads
Authors
Dear Editor,
We present a rare but clinically significant case of acute generalized exanthematous pustulosis (AGEP) following the administration of dupilumab in a patient with refractory atopic dermatitis (AD). While dupilumab is widely regarded as a safe and effective biologic agent for moderate-to-severe AD across age groups – including adolescents, adults, and increasingly children – emerging reports underscore the need to remain vigilant for uncommon, severe cutaneous reactions. [...]
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2020;156:44-56. DOI: https://doi.org/10.1001/jamadermatol.2019.3336
2. Grolleau C, Calugareanu A, Demouche S, et al. IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis. J Invest Dermatol 2023;143:711-21.e7. DOI: https://doi.org/10.1016/j.jid.2022.10.015
3. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol 2015;73:843-8. DOI: https://doi.org/10.1016/j.jaad.2015.07.017
4. Wu L, Ali K, Qiu Y, et al. Dupilumab-induced Acute Generalized Exanthematous Pustulosis in a 17-year-old Female Chinese Patient with Atopic Dermatitis. Acta Derm Venereol 2022;102:adv00743. DOI: https://doi.org/10.2340/actadv.v102.1079
5. Paller AS, Simpson EL, Siegfried EC, et al; participating investigators. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022;400:908-19. DOI: https://doi.org/10.1016/S0140-6736(22)01539-2
How to Cite
Acute generalized exanthematous pustulosis triggered by dupilumab. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10219
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
